Entacapone is a catechol-O-methyltransferase inhibitor used alongside levodopa/carbidopa to manage symptoms of Parkinson's disease.
Entacapone belongs to a group of medicines known as catechol-O-methyltransferase (COMT) inhibitors. Its main purpose is to help manage the motor symptoms of Parkinson’s disease by extending the effect of levodopa, a key treatment for the condition. In Hong Kong, entacapone is most commonly found in the combination product Stalevo.
The primary medication that includes entacapone in Hong Kong is Stalevo, a fixed-dose tablet that combines levodopa, carbidopa, and entacapone. Stalevo is available in several strengths, such as 100 mg/25 mg/200 mg and 200 mg/50 mg/200 mg, allowing doctors to tailor the dose to each patient’s needs. Generic versions of the individual components (levodopa, carbidopa, entacapone) are also licensed, but the combined tablet offers the convenience of taking one pill instead of separate ones. Stalevo is supplied by authorised pharmaceutical manufacturers and can be obtained from hospitals and community pharmacies with a prescription.
Entacapone itself is not used alone; it works alongside levodopa-based therapy to improve the control of Parkinson’s disease symptoms. Typical areas of benefit include:
These uses are recognised by the Hong Kong Department of Health and are reflected in the product’s official labeling. While entacapone is primarily approved for Parkinson’s disease, some clinicians may consider it in other situations where levodopa therapy needs enhancement, though such use would be off-label.
When levodopa is taken, the body quickly breaks it down, shortening its effect. Entacapone blocks the COMT enzyme that is responsible for this breakdown. By doing so, more levodopa remains available in the bloodstream, prolonging its action in the brain and smoothing out the peaks and troughs that cause motor fluctuations. The effect begins within a few hours after taking the tablet and lasts for the duration of levodopa therapy.
These symptoms are generally mild and may resolve without medical intervention.
If any of these occur, seek emergency medical care promptly.
Entacapone can interact with several other drug groups:
Patients are advised to review the full interaction list on the specific medication’s label and to avoid mixing alcohol excessively while on therapy.
Store Stalevo tablets at room temperature, away from moisture and direct sunlight. The tablets are intended for short-term adjustments to levodopa regimens, but treatment length varies based on individual needs. Always follow the directions printed on the medication’s packaging, as they contain essential information on how to take the tablet correctly. For precise dosing, timing, and any special instructions, refer to the specific product information that accompanies your prescription.
COMT inhibitor: A drug that blocks the enzyme catechol-O-methyltransferase, slowing the breakdown of levodopa. Levodopa: A precursor to dopamine used to replace the brain chemical lost in Parkinson’s disease. Carbidopa: A companion medicine that prevents levodopa from being converted to dopamine outside the brain, reducing side effects.
This article offers general educational information about entacapone as an active substance used in various medicines. Its purpose is to help patients better understand the ingredient and the conditions it is used to treat. It is not a substitute for professional medical advice or for the specific instructions provided with individual products. Medicines containing entacapone may differ in formulation, strength, and directions for use. Always consult the labeling of your particular medication and follow your healthcare provider’s guidance for complete information on proper use, dosage, and safety.
